Kseniya Vitalievna Kotova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kseniya Vitalievna Kotova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Gennadievna Ruksha
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
3 shared publications - Aleksandra R. Esimbekova
Krasnoyarsk State Medical University named after Professor V. F. Voyno-Yasenetsky
1 shared publication - Andreya Konstantinovich Kirichenko
FGUP I. P. Bardin TsNIIChermet, Moscow, Russia
1 shared publication - Daria A. Dashkova
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
1 shared publication - Evgenja Vladimirovna Okladnikova
Krasnoyarsk State Medical University named after Professor V. F. Voyno-Yasenetsky
1 shared publication - Victoriya Olegovna Tokmakova
Scientific research institute of medical problems of the North
1 shared publication
Latest Publications
- Open Access
- 8 March 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 27 (1) , 21-28
MiR-155-5p-mediated increase in p53 content induced by dacarbazine in melanoma cells
BACKGROUND: Cellular senescence is a stress response, triggered by various stimuli such as chemotherapy treatment and causes G0/G1 cell cycle arrest followed by the production of a senescence associated secretory phenotype. p53 considered to be a modulator of these events although the precise mechanisms of it remains not clear. AIMS: To determine the non-apoptotic functions of the p53 protein the formation of the senescence associated secretory phenotype phenotype of melanoma cells under the treatment of the cytostatic agent dacarbazine. MATERIALS AND METHODS: The study was conducted on BRO and SK-MEL-2 skin melanoma cell lines. Melanoma cells were were treated by cytostatic agent dacarbazine. Then immunocytochemical study was performed to determine the proportion of G0-positive cells and the expression of the tumor suppressor protein p53. A bioinformatic analysis was accomplished to identify for p53 regulators with determining of miR-155-5p levels in exosomes released by dacarbazine-treated melanoma cells. RESULTS: The cytostatic drug dacarbazine increases the proportion of cells residing in the G0 phase of the cell cycle. Onco-microRNA miR-155-5p was expressed in the exosomes of the two studied cell lines BRO and SK-MEL-2 of skin melanoma. Changes in the expression level of p53 correlate with changes in miR-155-5p microRNA expression. The absence of changes in p53 expression in BRO melanoma cells may be due to the absence of changes in miR-155-5p expression levels. In the BRO cell line, no changes in the expression of the oncosuppressor p53 were observed with an increased percentage of G0-positive cells, which may be associated with the activation of other mechanisms of cell cycle arrest in the G0/G1 phase. CONCLUSIONS: Heterogeneous effect of the cytostatic agent dacarbazine on melanoma cells was revealed. For the SK-MEL-2 cell line, dacarbazine induces the release of senescence associated secretory phenotype by inhibiting exosomal production of miR-155-5p, which activates the p53 oncosuppressor, which was not observed in the BRO line.
- 8 March 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 27 (1) , 21-28
Open AccessMiR-155-5p-mediated increase in p53 content induced by dacarbazine in melanoma cells
BACKGROUND: Cellular senescence is a stress response, triggered by various stimuli such as chemotherapy treatment and causes G0/G1 cell cycle arrest followed by the production of a senescence associated secretory phenotype. p53 considered to be a modulator of these events although the precise mechanisms of it remains not clear. AIMS: To determine the non-apoptotic functions of the p53 protein the formation of the senescence associated secretory phenotype phenotype of melanoma cells under the treatment of the cytostatic agent dacarbazine. MATERIALS AND METHODS: The study was conducted on BRO and SK-MEL-2 skin melanoma cell lines. Melanoma cells were were treated by cytostatic agent dacarbazine. Then immunocytochemical study was performed to determine the proportion of G0-positive cells and the expression of the tumor suppressor protein p53. A bioinformatic analysis was accomplished to identify for p53 regulators with determining of miR-155-5p levels in exosomes released by dacarbazine-treated melanoma cells. RESULTS: The cytostatic drug dacarbazine increases the proportion of cells residing in the G0 phase of the cell cycle. Onco-microRNA miR-155-5p was expressed in the exosomes of the two studied cell lines BRO and SK-MEL-2 of skin melanoma. Changes in the expression level of p53 correlate with changes in miR-155-5p microRNA expression. The absence of changes in p53 expression in BRO melanoma cells may be due to the absence of changes in miR-155-5p expression levels. In the BRO cell line, no changes in the expression of the oncosuppressor p53 were observed with an increased percentage of G0-positive cells, which may be associated with the activation of other mechanisms of cell cycle arrest in the G0/G1 phase. CONCLUSIONS: Heterogeneous effect of the cytostatic agent dacarbazine on melanoma cells was revealed. For the SK-MEL-2 cell line, dacarbazine induces the release of senescence associated secretory phenotype by inhibiting exosomal production of miR-155-5p, which activates the p53 oncosuppressor, which was not observed in the BRO line.
- Open Access
- 27 January 2023
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 98 (6) , 65-72
The role of proteins implicated in skin steroidogenesis in acne vulgaris development
Background. Acne vulgaris belongs to androgen-dependent diseases where androgens cause sebaceous gland hypertrophy with a subsequent enlargement of sebum production. Aims. Determination of the expression profile of steroidogenesis-related proteins in normal skin and skin of patients with acne. Material and methods. Immunohistochemical assay was carried out to characterize TSPO, StAR, CYP11A1, and 3-hydroxysteroid dehydrogenase expression in skin of patients with acne vulgaris and in normal skin. Results. Expression levels of a protein TSPO which is involved in a steroidogenesis-limited step was increased in mature sebocytes of acne vulgaris patients. StAR, CYP11A1, and 3-hydroxysteroid dehydrogenase immunovisualization was found both in normal skin and in the skin of acne patients. Conclusions. The revealed alterations in expression of steroidogenesis-related protein in acne skin may indicate not only the conversion of steroids produced by external steroidogenesis organs but elevated steroids local production as well. The fact may account both for sebaceous gland hyperplasia and inflammation sustenance in skin.
- 27 January 2023
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 98 (6) , 65-72
Open AccessThe role of proteins implicated in skin steroidogenesis in acne vulgaris development
Background. Acne vulgaris belongs to androgen-dependent diseases where androgens cause sebaceous gland hypertrophy with a subsequent enlargement of sebum production. Aims. Determination of the expression profile of steroidogenesis-related proteins in normal skin and skin of patients with acne. Material and methods. Immunohistochemical assay was carried out to characterize TSPO, StAR, CYP11A1, and 3-hydroxysteroid dehydrogenase expression in skin of patients with acne vulgaris and in normal skin. Results. Expression levels of a protein TSPO which is involved in a steroidogenesis-limited step was increased in mature sebocytes of acne vulgaris patients. StAR, CYP11A1, and 3-hydroxysteroid dehydrogenase immunovisualization was found both in normal skin and in the skin of acne patients. Conclusions. The revealed alterations in expression of steroidogenesis-related protein in acne skin may indicate not only the conversion of steroids produced by external steroidogenesis organs but elevated steroids local production as well. The fact may account both for sebaceous gland hyperplasia and inflammation sustenance in skin.
- Open Access
- 21 July 2022
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 98 (3) , 89-95
Pityriasis rubra pilaris (Devergie's disease) in a COVID-19 patient
Pityriasis rubra pilaris (Devergie's disease) is an idiopathic, papulosquamous inflammatory dermatosis characterized by progressive erythrodermia. The etiology of the disease is unknown, and most cases occur sporadically. Viral infections, impaired vitamin A metabolism, medications, autoimmune reactions, and malignancies are most common triggering factors. The diagnosis of Devergie's disease is based on the clinical manifestations of the disease and the results of a skin histological examination. The present paper discusses a clinical case of pityriasis rubra pilaris that occurred in a COVID-19, 40-year-old woman. For the purpose of differential diagnosis of pitiriasis with atopic dermatitis, erythrodermic form of psoriasis, generalized form of urticaria, it is necessary to perform immunohistochemical studies to identify the proliferation of immunocompetent cells. Based on the described clinical case, it seems possible to recommend testing for SARS-CoV-2 if a patient has Devergie's disease against the background of fever and intoxication syndrome.
- 21 July 2022
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 98 (3) , 89-95
Open AccessPityriasis rubra pilaris (Devergie's disease) in a COVID-19 patient
Pityriasis rubra pilaris (Devergie's disease) is an idiopathic, papulosquamous inflammatory dermatosis characterized by progressive erythrodermia. The etiology of the disease is unknown, and most cases occur sporadically. Viral infections, impaired vitamin A metabolism, medications, autoimmune reactions, and malignancies are most common triggering factors. The diagnosis of Devergie's disease is based on the clinical manifestations of the disease and the results of a skin histological examination. The present paper discusses a clinical case of pityriasis rubra pilaris that occurred in a COVID-19, 40-year-old woman. For the purpose of differential diagnosis of pitiriasis with atopic dermatitis, erythrodermic form of psoriasis, generalized form of urticaria, it is necessary to perform immunohistochemical studies to identify the proliferation of immunocompetent cells. Based on the described clinical case, it seems possible to recommend testing for SARS-CoV-2 if a patient has Devergie's disease against the background of fever and intoxication syndrome.